GCA
MCID: TMP003
MIFTS: 68

Temporal Arteritis (GCA)

Categories: Bone diseases, Cardiovascular diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Temporal Arteritis

MalaCards integrated aliases for Temporal Arteritis:

Name: Temporal Arteritis 57 12 53 54 59 15 17 72
Polymyalgia Rheumatica 57 12 75 59 37 55 43 44 15 17 72 33
Giant Cell Arteritis 57 12 75 53 54 59 37 43 44 15 72
Cranial Arteritis 57 53 54 72
Rhizomelic Pseudopolyarthritis 59 72
Horton's Disease 12 53
Horton Disease 75 59
Gca 57 53
Horton's Giant Cell Arteritis 53
Horton's Temporal Arteritis 53
Giant Cell Arteritis; Gca 57
Arteritis Temporalis 53
Arteritis Cranialis 53
Horton's Arteritis 53
Horton's Syndrome 53

Characteristics:

Orphanet epidemiological data:

59
giant cell arteritis
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Germany),1-5/10000 (United Kingdom),1-5/10000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
temporal arteritis:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:13375 DOID:853
OMIM 57 187360
ICD9CM 35 446.5 725
SNOMED-CT 68 65323003 87511001
ICD10 33 M31.5 M35.3
MESH via Orphanet 45 D013700
ICD10 via Orphanet 34 M31.6 M35.3
UMLS via Orphanet 73 C0032533 C0039483 C1527406 more
MedGen 42 C1956391
UMLS 72 C0032533 C0039483 C1527406 more

Summaries for Temporal Arteritis

KEGG : 37
Giant cell arteritis (GCA), also known as temporal arteritis, is a chronic and polygenic immune-mediated disease of unknown etiology. It is the most common form of vasculitis in individuals over the age of 50 in Western countries. It is characterized by inflammatory damage of the aorta and/or aortic branches, particularly the temporal artery, which can lead to severe complications such as blindness or cerebrovascular disorders. GCA is twice as common in women. It is frequently associated with polymyalgia rheumatica. Laboratory tests usually reveal high erythrocyte sedimentation rate (ESR), elevated levels of C-reactive protein (CRP) and other acute phase proteins, anemia of chronic disease, and thrombocytosis. Genetic association studies have described several genes that are associated with predisposition to GCA, including genes of immune-inflammatory pathways and genes of the HLA class I and II regions. The HLA-DRB1*04 alleles seem to be the most consistently associated genetic risk factors for GCA. Outside the HLA region, the most significant loci included PTPN22. Glucocorticoids are currently the mainstay of treatment for GCA but are associated with frequent adverse events. Tocilizumab, a humanised antihuman IL-6 receptor antibody, has been used successfully in several reports as a treatment of GCA.

MalaCards based summary : Temporal Arteritis, also known as polymyalgia rheumatica, is related to myocarditis and polyarteritis nodosa, and has symptoms including muscle weakness, angina pectoris and edema. An important gene associated with Temporal Arteritis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Bone Density Conservation Agents and Ibandronic Acid have been mentioned in the context of this disorder. Affiliated tissues include testes, tongue and bone, and related phenotypes are joint stiffness and fever

NIH Rare Diseases : 53 Giant cell arteritis (GCA) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels. GCA most commonly affects the arteries of the head (especially the temporal arteries, located on each side of the head), but arteries in other areas of the body can also become inflamed. The inflammation causes the arteries to narrow, resulting in poor blood flow. Signs and symptoms when arteries in the head are involved may include a throbbing headache on one side or the back of the head, tenderness of the scalp, flu-like symptoms, and/or problems with eyesight. Symptoms when other arteries are involved depend on the location of those arteries. The cause of GCA is still being studied, but it is thought to involve the immune system mistakenly attacking the artery walls. Several genetic and environmental factors may increase a person's risk to develop GCA. Complications of GCA may include permanent vision loss or a stroke, so treating the condition is important. Treatment may include corticosteroids and/or other medications that suppress the immune system. GCA may develop with or after another inflammatory disorder known as polymyalgia rheumatica, which occurs in about 40% to 50% of people with GCA.

MedlinePlus : 43 Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no single test to diagnose giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS : 54 Vasculitis is inflammation of blood vessels, which includes the veins, arteries, and capillaries. It occurs when the immune system mistakenly attacks a blood vessel. Vasculitis can also be caused by other immune system disease, an allergic reaction to medicines or toxins, and by certain blood cancers that trigger an immune system reaction. The resulting reduced blood flow can permanently damage the brain, spinal cord, peripheral nervous system, and other organs and tissue. Some forms of vasculitis affect a particular organ, whie others may affect many organs at the same time. Symptoms include headaches (especially a headache that doesn’t go away), fever, weight loss, confusion or forgetfulness leading to dementia, swelling of the brain, pain, vision problems, trouble speaking or understanding, muscle weakness and paralysis, and seizures. Some of the better understood vasculitis syndromes are temporal arteritis (also called giant cell arteritis or cranial arteritis--a chronic inflammatory disorder of large blood vessels) and Takayasu’s disease, which affects larger aortas and may cause stoke.

Wikipedia : 75 Giant-cell arteritis (GCA), also called temporal arteritis, is an inflammatory disease of large blood... more...

More information from OMIM: 187360

Related Diseases for Temporal Arteritis

Diseases in the Temporal Arteritis family:

Juvenile Temporal Arteritis

Diseases related to Temporal Arteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 844)
# Related Disease Score Top Affiliating Genes
1 myocarditis 32.8 TNF IL6 CD40LG
2 polyarteritis nodosa 31.1 IL6 CRP APOH
3 vasculitis 30.9 TNF CRP CD40LG CCL2 APOH
4 cold agglutinin disease 30.8 IL6 CRP
5 intermittent claudication 30.7 IL6 CRP APOH
6 arteriosclerosis 30.6 IL6 CRP CCL2
7 systemic scleroderma 30.5 IFNG CRP CD40LG
8 relapsing polychondritis 30.5 IL6 IFNG CRP
9 microscopic polyangiitis 30.5 TNF HLA-DRB1
10 peripheral artery disease 30.4 IL6 CRP CCL2
11 posterior scleritis 30.3 TNFRSF10A TNF
12 extrapulmonary tuberculosis 30.3 IL1RN IFNG CCL2
13 end stage renal failure 30.3 TNF IL6 CRP
14 lyme disease 30.2 TNF IL6 CRP CD40LG
15 scleritis 30.2 TNF IFNG
16 castleman disease 30.2 IL6 IFNG CRP
17 chlamydia 30.1 TNF IL6 IFNG CRP
18 myelitis 30.1 TNF IL6 APOH
19 proliferative glomerulonephritis 30.1 IL6 IFNG CCL2
20 graves' disease 30.1 PTPN22 IFNG HLA-DRB1
21 bronchiolitis obliterans 30.1 TNF IL6 IFNG
22 alopecia areata 30.0 TNF PTPN22 IL1RN IFNG
23 spotted fever 30.0 TNF IFNG CCL5
24 uveitis 30.0 TNF IFNG CCL2
25 retinal vein occlusion 30.0 IL6 CCL2 APOH
26 reactive arthritis 30.0 TNF IFNG CRP
27 takayasu arteritis 30.0 TNF IL6 HLA-DRB1 CRP
28 pleurisy 30.0 TNF IFNG CRP CCL2
29 pustulosis of palm and sole 30.0 TNF IL1RN
30 inflammatory bowel disease 29.9 TNF IL6 IFNG CRP
31 arteries, anomalies of 29.9 TNF IL6 CRP CCL2
32 endocarditis 29.9 TNF IL6 CRP APOH
33 vascular disease 29.9 TNF IL6 CRP CCL2 APOH
34 anca-associated vasculitis 29.9 IL6 HLA-DRB1
35 diabetes mellitus, insulin-dependent 29.9 PTPN22 IL6 IFNG HLA-DRB1
36 leishmaniasis 29.9 TNF IFNG HLA-DRB1
37 cerebrovascular disease 29.9 TNF IL6 CRP
38 exanthem 29.9 TNF IL6 IL1RN CRP
39 toxic shock syndrome 29.9 TNF IL6 IFNG
40 neuritis 29.9 TNF IFNG CCL5 CCL2
41 glossitis 29.8 TNF IL6
42 infective endocarditis 29.8 TNF IL6 CRP APOH
43 purpura 29.8 TNF IL6 CRP APOH
44 sarcoidosis 1 29.8 TNF IFNG HLA-DRB1
45 contact dermatitis 29.8 TNF IL6 IFNG
46 spondylitis 29.8 TNF IL6 IL1RN CRP
47 rheumatic fever 29.7 TNF IL6 HLA-DRB1
48 q fever 29.7 TNF IL6 IFNG
49 spondyloarthropathy 29.7 TNF IL6 IFNG
50 lupus erythematosus 29.7 TNF PTPN22 CD40LG APOH

Comorbidity relations with Temporal Arteritis via Phenotypic Disease Network (PDN): (show all 22)


Active Peptic Ulcer Disease Acute Cystitis
Aortic Valve Disease 1 Bronchitis
Cerebral Arteritis Conn's Syndrome
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Mitral Valve Disease Nonarteritic Anterior Ischemic Optic Neuropathy
Optic Neuritis Osteoporosis
Polymyositis Premature Ovarian Failure 7
Rheumatoid Arthritis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Temporal Arteritis:



Diseases related to Temporal Arteritis

Symptoms & Phenotypes for Temporal Arteritis

Human phenotypes related to Temporal Arteritis:

59 32 (show top 50) (show all 59)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 joint stiffness 59 32 hallmark (90%) Very frequent (99-80%) HP:0001387
2 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
3 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
4 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
5 anorexia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002039
6 cerebral ischemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002637
7 headache 59 32 hallmark (90%) Very frequent (99-80%) HP:0002315
8 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
9 impaired mastication 59 32 hallmark (90%) Very frequent (99-80%) HP:0005216
10 depressivity 59 32 frequent (33%) Frequent (79-30%) HP:0000716
11 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
12 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
13 ophthalmoparesis 59 32 frequent (33%) Frequent (79-30%) HP:0000597
14 elevated erythrocyte sedimentation rate 59 32 frequent (33%) Frequent (79-30%) HP:0003565
15 ptosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000508
16 nystagmus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000639
17 diplopia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000651
18 hyperhidrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000975
19 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
20 muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0001324
21 sudden cardiac death 59 32 occasional (7.5%) Occasional (29-5%) HP:0001645
22 optic atrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0000648
23 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
24 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
25 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
26 skin ulcer 59 32 occasional (7.5%) Occasional (29-5%) HP:0200042
27 hematuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000790
28 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
29 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
30 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
31 gangrene 59 32 occasional (7.5%) Occasional (29-5%) HP:0100758
32 abnormality of the pleura 59 32 occasional (7.5%) Occasional (29-5%) HP:0002103
33 aortic dissection 59 32 occasional (7.5%) Occasional (29-5%) HP:0002647
34 visual field defect 59 32 occasional (7.5%) Occasional (29-5%) HP:0001123
35 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
36 amaurosis fugax 59 32 occasional (7.5%) Occasional (29-5%) HP:0100576
37 diabetes insipidus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000873
38 vertigo 59 32 occasional (7.5%) Occasional (29-5%) HP:0002321
39 visual loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0000572
40 hepatic failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001399
41 conductive hearing impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000405
42 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
43 recurrent pharyngitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100776
44 meningitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001287
45 arterial thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004420
46 mediastinal lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100721
47 gastrointestinal infarctions 59 32 occasional (7.5%) Occasional (29-5%) HP:0005244
48 glossitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000206
49 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0011658
50 abdominal aortic aneurysm 32 occasional (7.5%) HP:0005112

Symptoms via clinical synopsis from OMIM:

57
Eyes:
blindness
retinal arteritis

Lab:
elevated sedimentation rate

Vascular:
temporal arteritis
giant cell arteritis
polymyalgia rheumatica (pmr)

Misc:
response to adrenal glucocorticoids

Clinical features from OMIM:

187360

UMLS symptoms related to Temporal Arteritis:


muscle weakness, angina pectoris, edema, pruritus, myalgia, chest pain, back pain, sciatica, exanthema, muscle cramp, muscle rigidity, muscle spasticity

MGI Mouse Phenotypes related to Temporal Arteritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.02 CD4 CD40LG CD8A IFNG IL1RN IL6
2 hematopoietic system MP:0005397 9.96 CCL5 CD4 CD40LG CD8A IFNG IL1RN
3 endocrine/exocrine gland MP:0005379 9.92 CD4 CD40LG CD8A IFNG IL6 PTPN22
4 homeostasis/metabolism MP:0005376 9.85 APOH CD4 CD40LG CRP IFNG IL1RN
5 immune system MP:0005387 9.73 CCL2 CCL5 CD4 CD40LG CD8A CRP
6 integument MP:0010771 9.17 CD4 CD40LG CD8A IFNG IL1RN IL6

Drugs & Therapeutics for Temporal Arteritis

Drugs for Temporal Arteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Bone Density Conservation Agents Phase 4
2 Ibandronic Acid Phase 4
3 Omega 3 Fatty Acid Phase 4
4
Infliximab Approved Phase 3 170277-31-3
5
Adalimumab Approved Phase 3 331731-18-1 16219006
6
Hydroxychloroquine Approved Phase 3 118-42-3 3652
7
Etanercept Approved, Investigational Phase 3 185243-69-0
8
Alendronate Approved Phase 3 66376-36-1, 121268-17-5 2088
9
Metformin Approved Phase 2, Phase 3 657-24-9 4091 14219
10
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
11
Racepinephrine Approved Phase 3 329-65-7 838
12
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
13
leucovorin Approved Phase 3 58-05-9 143 6006
14
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
15
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
16
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
19 Upadacitinib Investigational Phase 3 1310726-60-3
20 Antiparasitic Agents Phase 3
21 Antimalarials Phase 3
22 Antiprotozoal Agents Phase 3
23 Anti-Inflammatory Agents, Non-Steroidal Phase 3
24 Micronutrients Phase 3
25 Trace Elements Phase 3
26 Vitamins Phase 3
27 Hydroxycholecalciferols Phase 3
28 Nutrients Phase 3
29 Calciferol Phase 3
30 Hypoglycemic Agents Phase 2, Phase 3
31 Pharmaceutical Solutions Phase 3
32 Gastrointestinal Agents Phase 3
33 Antiemetics Phase 3
34 Neuroprotective Agents Phase 3
35 Peripheral Nervous System Agents Phase 3
36 Protective Agents Phase 3
37 Autonomic Agents Phase 3
38 Epinephryl borate Phase 3
39 Folic Acid Antagonists Phase 3
40 Vitamin B9 Phase 3
41 Nucleic Acid Synthesis Inhibitors Phase 3
42 Vitamin B Complex Phase 3
43 Folate Phase 3
44 Antimetabolites Phase 3
45 Antimetabolites, Antineoplastic Phase 3
46 Interleukin 1 Receptor Antagonist Protein Phase 3
47 Antihypertensive Agents Phase 3
48 Endothelin Receptor Antagonists Phase 3
49
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
50
Ethanol Approved Phase 2 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission: a Prospective, Pilot Study. Unknown status NCT03244709 Phase 4 Tocilizumab
2 Study the Link Between Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
3 Short Term Study on the Effect of a Fixed Dose of 12.5 mg of Prednisone as Starting Dose in Polymyalgia Rheumatica Completed NCT01169597 Phase 4 prednisone
4 Efficacy of Monthly Ibandronate in Women With Rheumatoid Arthritis and Reduced Bone Mineral Density Receiving Long-term Glucocorticoids Completed NCT01287533 Phase 4 Ibandronate;Placebo
5 Tocilizumab Plus a Short Prednisone Taper for Giant Cell Arteritis (GCA) Recruiting NCT03726749 Phase 4 Tocilizumab;Prednisone
6 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
7 Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica: a Double Blind Placebo Controlled Trial Unknown status NCT01423591 Phase 3 infliximab;inactive powder
8 Threecenter Placebo Controlled Three Arm Trial in Patients With Active Ankylosing Spondylitis With Prednisolone Unknown status NCT00244166 Phase 2, Phase 3 prednisolone
9 HECTHOR: A Pilot Multicenter Double-blind Randomised Study of 3 Months Treatment With Humira Added to Steroids in Giant Cell Arteritis Completed NCT00305539 Phase 3 adalimumab;placebo
10 Multicentric Double Blind Versus Placebo Randomised Study Evaluating the Corticosteroid Sparing Effect of Hydrocyschloroquine in Non Complicated Giant Cell Arteritis. Completed NCT00430807 Phase 3 hydroxychloroquine/placebo
11 The Effect of Etanercept on the Early Clinical Course of Polymyalgia Rheumatica (Pilot Study) Completed NCT00524381 Phase 3 Etanercept (Enbrel);Sodium chloride (placebo)
12 A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis Completed NCT01791153 Phase 3 Tocilizumab;Prednisone;Tocilizumab Placebo;Prednisone Placebo;Corticosteroids;Methotrexate
13 Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
14 Circadian Variation in Cytokines and the Effect of Timed Release Tablet Prednisone in Polymyalgia Rheumatica Completed NCT00836810 Phase 2, Phase 3 Timed Release Tablet Prednisone;Prednisolone
15 Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
16 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Giant Cell Arteritis Recruiting NCT03725202 Phase 3 Upadacitinib;Corticosteroid (CS)
17 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis Recruiting NCT03600805 Phase 3 Sarilumab SAR153191;Sarilumab matching placebo;Prednisone;Prednisone matching placebo
18 To Demonstrate the Ability of Abatacept in Comparison to Placebo to Obtain a Low Disease Activity [PMR-AS (CRP) Lower or Equal to 10] Without GCs (Prednisone or Prednisolone) at Week 12 in Early Onset PMR Patients. Recruiting NCT03632187 Phase 3 Abatacept;Placebos
19 A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Recruiting NCT03600818 Phase 3 Sarilumab SAR153191 (REGN88);Sarilumab-matching placebo;Prednisone;Prednisone-matching placebo;Prednisone
20 Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE Recruiting NCT02908217 Phase 3 Tocilizumab;Placebo
21 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Recruiting NCT03263715 Phase 3 Tocilizumab Prefilled Syringe [Actemra];Placebos;Glucocorticoids
22 A Multicenter Randomized Placebo Controlled Treatment Study of Leflunomide in Polymyalgia Rheumatica Recruiting NCT03576794 Phase 3 Leflunomide 20 mg;Prednisolone
23 An Extension Study to Evaluate Long Term Safety of Subcutaneous Tocilizumab in Patients With Giant Cell Arteritis Who Have Completed WA28119 Core Study in France, and Subsequently Having Flare or Persisting Disease Activity. Active, not recruiting NCT03202368 Phase 3 Tocilizumab
24 A Randomized, Controled, Open Label Trial: Comparison Between Two Standardised Corticosteroids Tapering, Respectively Short (North American) and Long (European), in Giant Cell Arteritis Not yet recruiting NCT04012905 Phase 3 Corticosteroids for Systemic Use
25 MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial Not yet recruiting NCT03892785 Phase 3 Prednisone treatment;Tocilizumab treatment;Methotrexate treatment
26 Randomized, Controlled, Double-blind Study of Anakinra Against Placebo in Addition to Steroids in Giant Cell Arteritis Not yet recruiting NCT02902731 Phase 3 PLACEBO;ANAKINRA
27 Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO Not yet recruiting NCT03841734 Phase 3 treatment
28 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis Terminated NCT02531633 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone;Placebo to match prednisone
29 A Randomised, Multi-centre, Double-blind, Active-controlled, Parallel Group Study to Assess the Efficacy and Safety of Modified Release Prednisone (Lodotra®) Compared to Immediate Release Prednisone (Prednisone IR) in Subjects Suffering From Polymyalgia Rheumatica (PMR). Terminated NCT01821040 Phase 3 Lodotra®;Prednisone IR (immediate release)
30 A Phase III Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Combination With Glucocorticoid Treatment Compared to Glucocorticoid Monotherapy in Adults With Giant Cell Arteritis Withdrawn NCT03192969 Phase 3 Abatacept;Glucocorticoid Treatment
31 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Polymyalgia Rheumatica Withdrawn NCT02899026 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone /Prednisone placebo
32 A Phase II, Randomized, Double-blind, Placebo Controlled Study of Tocilizumab in Patients With Giant Cell Arteritis Completed NCT01450137 Phase 2 Tocilizumab + Glucocorticoids (GCs);Placebo + Glucocorticoids (GCs)
33 Concurrent Pilot Studies in Giant Cell Arteritis and Takayasu's Arteritis to Examine the Safety, Efficacy, and Immunologic Effects of Abatacept (CTLA4-Ig) in Large Vessel Vasculitis Completed NCT00556439 Phase 2 Abatacept;Placebo
34 Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. Completed NCT01910038 Phase 2 corticoids+ tocilizumab 8mg/Kg/4 weeks
35 Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis Completed NCT00004686 Phase 2 methotrexate;prednisone
36 Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR) Completed NCT01713842 Phase 2 TCZ
37 Phase IIa of Tocilizumab In the Treatment of Polymyalgia Rheumatica Completed NCT01396317 Phase 2 Tocilizumab
38 Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
39 A Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell Arteritis Recruiting NCT03827018 Phase 2
40 Baricitinib in Relapsing Giant Cell Arteritis (GCA): A Phase II, Single-institution, Open-label Pilot Study Recruiting NCT03026504 Phase 2 Baricitinib
41 A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab (AIN457) in Patients With Giant Cell Arteritis (TitAIN) Recruiting NCT03765788 Phase 2 Prednisolone;Placebo to match Secukinumab, s.c.
42 Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis Recruiting NCT03711448 Phase 2 prednisone treatment;prednisone and ustekinumab treatment
43 Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Recruiting NCT03745586 Phase 1, Phase 2 Tocilizumab;Glucocorticoids
44 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
45 Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study Recruiting NCT03446209 Phase 2 Tocilizumab Infusion RoAcemtra (EU);0.9% physiological saline
46 Open Label Study to Test the Safety and Efficacy of Ustekinumab in Patients With Giant Cell Arteritis Active, not recruiting NCT02955147 Phase 1, Phase 2 Ustekinumab;Prednisone
47 Evaluating the Use of Gallium-68 HA-DOTATATE Positron Emission Tomography/Computerized Tomography (PET/CT) in Patients With Giant Cell Arteritis (GCA.) Not yet recruiting NCT03812302 Phase 2
48 Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica Not yet recruiting NCT04062006 Phase 2 Interleukin-2
49 BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica (BACHELOR Study) Not yet recruiting NCT04027101 Phase 2 Baricitinib;Placebos
50 A Randomized, Open-label, Dose-ranging Study of Oral Delayed Release Prednisone in Patients With Untreated Polymyalgia Rheumatic (PMR) Terminated NCT02702778 Phase 2 Delayed-Release (DR) Prednisone;Immediate Release (IR) Prednisone

Search NIH Clinical Center for Temporal Arteritis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Betamethasone
Bupivacaine
Prednisolone
Prednisone
tocilizumab
Triamcinolone

Cochrane evidence based reviews: giant cell arteritis

Genetic Tests for Temporal Arteritis

Anatomical Context for Temporal Arteritis

MalaCards organs/tissues related to Temporal Arteritis:

41
Testes, Tongue, Bone, Skin, Eye, Brain, Spinal Cord

Publications for Temporal Arteritis

Articles related to Temporal Arteritis:

(show top 50) (show all 4190)
# Title Authors PMID Year
1
Polymyalgia rheumatica and giant-cell arteritis. 38 8
12140303 2002
2
Familial occurrence of temporal arteritis. 38 8
9058678 1997
3
Familial association of giant cell arteritis. A case report and brief review. 38 8
7447573 1981
4
Familial polymyalgia rheumatica. 38 8
7268390 1981
5
Familial aggregation of polymyalgia rheumatica and giant cell arteritis. 38 8
4810661 1974
6
The different clinical patterns of giant cell arteritis. 38 17
31162029 2019
7
Paraneoplastic Syndrome Presenting with Polymyalgia Rheumatica-like Accumulations on 18F-fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography. 38 17
30449806 2019
8
Comorbidities in polymyalgia rheumatica: a systematic review. 38 17
30458857 2018
9
New insights into the pathogenesis of giant cell arteritis and hopes for the clinic. 38 6
26367100 2016
10
Giant cell arteritis in Asians: a comparative study. 8
20584707 2011
11
Giant cell arteritis among Hispanic Americans. 8
17188057 2007
12
Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. 8
12799248 2003
13
The role of unilateral temporal artery biopsy. 8
12623818 2003
14
Thrombocytosis in patients with biopsy-proven giant cell arteritis. 8
12093648 2002
15
Increased endothelin-1 plasma levels in giant cell arteritis: a report on four patients. 8
11755863 2002
16
The epidemiology of giant cell arteritis : a 12-year retrospective study. 8
11382644 2001
17
The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. 8
1469092 1992
18
Effects of incision location on specimen quality and complications for temporal artery biopsy. 17
31313985 2019
19
Acetylcholinesterase-associated inflammation in patients with giant cell arteritis. Evaluation by histology and 11C-donepezil PET/CT. 17
31162030 2019
20
Cytokine expression in temporal arteries: comparative analysis between patients with biopsy-positive giant cell arteritis, biopsy-negative giant cell arteritis and biopsy-negative without arteritis. 17
31162032 2019
21
Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: Association of IL-1RN*2/2 genotype with polymyalgia rheumatica. 9 38
19026700 2009
22
HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: influence on clinical subgroups and prognosis. 9 38
15305244 2004
23
Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. 9 38
15194587 2004
24
[Serum amyloid A as a useful index of disease activity in polymyalgia rheumatica]. 9 38
12910963 2003
25
RANTES gene polymorphism in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis. 9 38
10895380 2000
26
Favorable role of interleukin 10 in patients with polymyalgia rheumatica. 9 38
10381050 1999
27
HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. 9 38
10225816 1999
28
Cytokines and adhesion molecules in patients with polymyalgia rheumatica. 9 38
9714354 1998
29
Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis. 9 38
9714363 1998
30
Distribution of HLA-DRB1 alleles of patients with polymyalgia rheumatica and giant cell arteritis in a Mediterranean population. 9 38
9458210 1998
31
Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis. 9 38
7677440 1995
32
The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica. 9 38
7641508 1995
33
[HLA DRB1 polymorphism in rhizomelic pseudo-polyarthritis and Horton disease]. 9 38
8525160 1995
34
HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis. 9 38
8147928 1994
35
[Complement activation by C-reactive protein in various inflammatory diseases (in vitro)]. 9 38
1563753 1992
36
[Glycoforms of serum alpha 1-antichymotrypsin studied by immunoaffino-electrophoresis. From the fundamental aspect to clinical applications]. 9 38
1759731 1991
37
Microheterogeneity of acute phase proteins in the differentiation of polymyalgia rheumatica from polymyositis. 9 38
1705291 1990
38
Association of osteoarthritis with homozygosity for a 5.8 kb Taq I fragment of the alpha 1-antichymotrypsin gene. 9 38
1974162 1990
39
Microheterogeneity of alpha 1-antichymotrypsin in the management of giant-cell arteritis and polymyalgia rheumatica. 9 38
2165887 1990
40
Prevalence of polymyalgia rheumatica in Colombia: data from the national health registry 2012-2016. 38
31327052 2019
41
Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. 38
30692587 2019
42
A case of inflammatory pseudotumor of the lung presenting as polymyalgia rheumatica. 38
31428379 2019
43
Additional Costs of Polymyalgia Rheumatica With Giant Cell Arteritis. 38
30156754 2019
44
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica. 38
31402523 2019
45
Subclinical atherosclerosis and endothelial dysfunction in patients with polymyalgia rheumatica: a pilot study. 38
31418315 2019
46
[Polyarteritis nodosa, an alternative diagnosis of giant cell arteritis in cases of temporal arteritis]. 38
31201015 2019
47
Use of high-resolution vessel wall magnetic resonance imaging in the diagnosis of temporal arteritis. 38
30993399 2019
48
Treatment of polymyalgia rheumatica. 38
30904473 2019
49
Polymyalgia rheumatica due to pembrolizumab therapy. 38
30249155 2019
50
Giant cell arteritis without cranial manifestations caused mesenteric involvement: a case report. 38
31342194 2019

Variations for Temporal Arteritis

Expression for Temporal Arteritis

Search GEO for disease gene expression data for Temporal Arteritis.

Pathways for Temporal Arteritis

Pathways related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 TNF SERPINA3 PTPN22 IL6 IL1RN IFNG
2
Show member pathways
13.63 TNFRSF10A TNF IL6 IL1RN IFNG CD40LG
3
Show member pathways
13.49 TNFRSF10A TNF IL6 IFNG CD4 CCL5
4
Show member pathways
13.38 TNFRSF10A TNF IL6 CD40LG CD4 CCL5
5
Show member pathways
13.29 TNF IL6 IL1RN IFNG HLA-DRB1 CD40LG
6
Show member pathways
13.26 TNFRSF10A TNF PTPN22 IL6 CD40LG CD4
7
Show member pathways
13.04 TNF IL6 IFNG CCL5 CCL2
8
Show member pathways
12.94 TNFRSF10A TNF IL6 CD4 CCL5 CCL2
9
Show member pathways
12.91 TNF IL6 CD4 CCL5 CCL2
10
Show member pathways
12.82 TNF IL6 IFNG HLA-DRB1 CD8A CD40LG
11
Show member pathways
12.62 TNF IFNG HLA-DRB1 CD40LG CD4
12
Show member pathways
12.59 TNF IL6 IFNG HLA-DRB1 CD4
13
Show member pathways
12.58 TNF IL6 IFNG CD4 CCL2
14
Show member pathways
12.51 TNF IL6 IFNG CD8A CD40LG CD4
15
Show member pathways
12.33 TNF IL6 IFNG CCL2
16
Show member pathways
12.26 TNF IFNG HLA-DRB1 CD40LG
17 12.23 TNF IL6 IFNG HLA-DRB1
18
Show member pathways
12.2 TNF SERPINA3 IL6 IFNG CRP CCL5
19 12.12 HLA-DRB1 CD8A CD40LG CD4
20 12.07 TNF PTPN22 IL1RN IFNG CD8A CD40LG
21
Show member pathways
12.05 TNF IL6 IFNG CD4
22
Show member pathways
12.04 TNFRSF10A IL6 IFNG CD4 CCL5 CCL2
23 12.01 TNF IL6 IFNG CCL2
24
Show member pathways
11.99 TNF IL6 IFNG
25
Show member pathways
11.97 IFNG HLA-DRB1 CD8A CD4
26 11.97 TNF IL6 IFNG CD8A CD4
27 11.96 TNF IL6 CCL5 CCL2
28 11.95 TNF IL6 CCL2
29
Show member pathways
11.92 PTPN22 HLA-DRB1 CD4
30
Show member pathways
11.92 HLA-DRB1 CD8A CD4
31 11.89 TNF IL6 IFNG
32 11.88 TNF IL6 CCL2
33 11.86 TNF IL6 HLA-DRB1 CD8A CD4
34 11.8 TNF IFNG CD8A CD4
35
Show member pathways
11.75 TNF IFNG CD40LG
36 11.74 PTPN22 HLA-DRB1 CD8A CD4
37 11.7 TNF IL6 IFNG CD8A CD4
38 11.7 TNF IL6 IFNG HLA-DRB1 CCL5 CCL2
39
Show member pathways
11.67 TNF IL6 IFNG CD40LG
40 11.66 TNF IL6 CCL5 CCL2
41
Show member pathways
11.65 TNF IFNG CD8A
42 11.57 TNF IL6 IFNG
43 11.53 TNF IFNG CCL2
44 11.5 TNF IL6 IFNG
45 11.49 TNF IL6 IFNG CD40LG CCL2
46 11.46 TNF IL6 IL1RN CCL5 CCL2
47 11.41 CD8A CD40LG CD4
48 11.39 TNF IL6 IFNG
49 11.32 TNF IL6 IFNG
50 11.25 IFNG HLA-DRB1 CD4

GO Terms for Temporal Arteritis

Cellular components related to Temporal Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.65 TNF HLA-DRB1 CD8A CD40LG CD4
2 extracellular space GO:0005615 9.65 TNF SERPINA3 IL6 IL1RN IFNG CRP
3 cell surface GO:0009986 9.63 TNFRSF10A TNF HLA-DRB1 CD40LG CD4 APOH
4 extracellular region GO:0005576 9.36 TNF SERPINA3 IL6 IL1RN IFNG CRP
5 T cell receptor complex GO:0042101 9.32 CD8A CD4

Biological processes related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 TNF PTPN22 IL6 IFNG CRP
2 cellular response to lipopolysaccharide GO:0071222 9.85 TNF IL6 IL1RN CCL2
3 cell surface receptor signaling pathway GO:0007166 9.85 TNFRSF10A IFNG CD8A CD4 CCL2
4 T cell receptor signaling pathway GO:0050852 9.84 PTPN22 HLA-DRB1 CD4
5 response to virus GO:0009615 9.83 TNF IFNG CCL5
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 TNF PTPN22 CD4 CCL5 CCL2
7 defense response to Gram-positive bacterium GO:0050830 9.82 TNF IL6 CRP
8 neutrophil chemotaxis GO:0030593 9.82 IL1RN CCL5 CCL2
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 IL6 IFNG CCL5
10 cellular response to organic cyclic compound GO:0071407 9.8 TNF CCL5 CCL2
11 response to glucocorticoid GO:0051384 9.8 TNF IL6 IL1RN
12 regulation of insulin secretion GO:0050796 9.79 TNF IFNG CCL5
13 positive regulation of interleukin-6 production GO:0032755 9.78 TNF IL6 IL1RN
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 TNF IL6 CCL5
15 extrinsic apoptotic signaling pathway GO:0097191 9.73 TNFRSF10A TNF IFNG
16 cytokine-mediated signaling pathway GO:0019221 9.73 TNF IL6 IL1RN CD4 CCL5 CCL2
17 monocyte chemotaxis GO:0002548 9.71 IL6 CCL5 CCL2
18 positive regulation of T cell proliferation GO:0042102 9.71 IL6 CD40LG CD4 CCL5
19 protein kinase B signaling GO:0043491 9.7 TNF CCL5 CCL2
20 acute-phase response GO:0006953 9.67 SERPINA3 IL6 CRP
21 humoral immune response GO:0006959 9.67 TNF IL6 IFNG CCL2
22 positive regulation of glial cell proliferation GO:0060252 9.66 TNF IL6
23 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.66 TNF IFNG
24 macrophage chemotaxis GO:0048246 9.65 CCL5 CCL2
25 regulation of T cell activation GO:0050863 9.64 CD4 CCL5
26 positive regulation of neuroinflammatory response GO:0150078 9.61 TNF IL6
27 regulation of immunoglobulin secretion GO:0051023 9.59 TNF CD40LG
28 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.58 IL6 IL1RN
29 inflammatory response GO:0006954 9.56 TNF SERPINA3 IL6 IL1RN CRP CD40LG
30 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 TNF IFNG
31 negative regulation of lipid storage GO:0010888 9.5 TNF IL6 CRP
32 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 TNF IFNG
33 lipopolysaccharide-mediated signaling pathway GO:0031663 9.46 TNF PTPN22 CCL5 CCL2
34 immune response GO:0006955 9.32 TNF IL6 IL1RN IFNG HLA-DRB1 CD8A
35 chronic inflammatory response to antigenic stimulus GO:0002439 9.27 TNF

Molecular functions related to Temporal Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 TNFRSF10A TNF SERPINA3 PTPN22 IL6 IL1RN
2 cytokine activity GO:0005125 9.17 TNF IL6 IL1RN IFNG CD40LG CCL5

Sources for Temporal Arteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....